Abstract 1985P
Background
Sarcomas are rare mesenchymal tumors that require multidisciplinary care. Referral centres receiving patients (pts) from peripheral set-ups face challenges which highlight the need for expert sarcoma pathology and specialised treatment.
Methods
This is a retrospective study in pts referred with pathological and/or clinico-radiological diagnosis of sarcoma (January 2021 to December 2022). Clinical, diagnostic, prior treatment details were reviewed from records. Pathologic discordances (PD) were classified as major (sarcoma to carcinoma or benign, soft tissue sarcoma to bone sarcoma or vice versa, any change influencing treatment) or minor.
Results
539 pts included (incl) 58% males (n=312) with median age of 35 (1-89 years), residing at median distance of 160 kilometres (km) (3-2600) from our centre. Median presenting time was 11 months (15 days-20 years) from symptom onset; recurrent/metastatic (n=255, 47%) and locally advanced (n=134, 25%) stages predominated. Common primary sites were extremity (45.5%), abdomen (27%) with symptoms of pain (67%) and swelling (64%). 499 (92.5%) pts had pathology reports from outside and available comparison (n=372) showed 42.9% discordance (16.3% major, 26.6% minor) (Table). Sarcoma diagnosis changed to benign (1.3%), carcinoma (1.3%), fibromatosis (0.2%), germ cell tumor (0.2%) after review. Ultra-rare sarcomas (URS) (n=33, 6%) showed higher PD (73%). Molecular testing was done in 4.6% (n=11) of pts with testing indications. Most had received treatment outside (surgery in 50.6%, chemotherapy in 32.6%); deviation from standard guidelines was noted in 39.7% chemotherapy and 8.7% surgeries (Table). Univariate analysis did not yield significant factors associated with diagnostic or treatment discordance. Table: 1985P
Details of subjects and discordances in diagnosis and treatment
Diagnosis | Treatment |
Subtypes Soft tissue sarcoma (STS) = 295 (54.7%) Bone sarcoma (BS) = 100 (18.5%) Carcinoma = 7 (1.2%) Benign = 7 (1.2%) Others = 10 (2%) Undifferentiated = 1 (0.2%) Discordances a) Major = 61 (16.3%) b) Minor = 99 (26.6%) Major discordance: a) Change of sarcoma subtype = 39 (64%) b) Benign to malignant = 14 (11.7%) c) Carcinoma to sarcoma = 4 (6.5%) d) Low to high grade = 4 (6.5%) e) BS to STS = 3 (5%) | Chemotherapy a) Incorrect regimen (n=28, 16%) b) Inadequate dose/cycles (n=20, 11.3%) c) Not given despite indication (n=17, 9.6%) d) Others (n=4, 2.2%) Surgery a) Inadequate surgery (n=19, 7%) b) Surgery without staging (n=5, 2%) |
Conclusions
The significant discrepancies noted in diagnosis and management of pts in this study highlight the importance of expert pathologists and early referral for better treatment outcomes in sarcomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15
1960P - Clinical outcomes of the patients with alveolar soft part sarcoma developed brain metastasis
Presenter: Yu Toda
Session: Poster session 15
1961P - Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
Presenter: Khomsit Thongthammachat
Session: Poster session 15
1963P - Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Presenter: Marina Voropaeva
Session: Poster session 15
1964P - Biomimetics of three-dimensional (3D) osteosarcoma (OS) models: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 15
1965P - Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Presenter: Jason Roszik
Session: Poster session 15
1966P - Extending the interval of denosumab treatment for unresectable giant cell tumor of bone
Presenter: Toshiyuki Kunisada
Session: Poster session 15
1967P - A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIb classic osteosarcoma of the extremity
Presenter: Fan Tang
Session: Poster session 15
1968P - Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1969P - Intratumoral immune infiltrates in chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 15